DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/d6650b/dyskinesia_therape) has announced the addition of GlobalData's new report "Dyskinesia Therapeutics - Pipeline Assessment and Market Forecasts to 2019" to their offering.
The Dyskinesia Therapeutics Market is Forecast to Show Moderate Growth until 2019
The global market for dyskinesia therapeutics was valued at approximately $302.3m in 2011 and is expected to reach $480m by 2019 at a Compound Annual Growth Rate (CAGR) of 6%.
The dyskinesia therapeutics market is derived from the patient pool of Levodopa-Induced Dyskinesia (LID) and Tardive Dyskinesia (TD). LID is caused by levodopa, a widely used treatment option for Parkinson's disease (PD). The continuing usage of levodopa in PD has resulted in an increase in the prevalence of LID. At present amantadine is used for LID as an adjuvant treatment to levodopa. TD is caused by long-term use of the antipsychotics currently prescribed for various psychiatric disorders such as schizophrenia, bipolar disorder, depression and others.
The antipsychotics prescription pattern has witnessed a shift from the typical antipsychotics (such as haloperidol) to atypical antipsychotics (such as olanzapine, aripiprazole, quetiapine, risperidone and others). This shift has resulted in a reduction in the risk of TD.
According to the National Institute of Neurological Disorders and Stroke (NINDS), tetrabenazine is the preferred off-label treatment option for TD, despite not being currently approved for dyskinesia by regulatory bodies such as the Food and Drug Administration (FDA) in the US, the European Medical Agency (EMEA), or others. The late stage dyskinesia pipeline has only one molecule, ADS-5102 (Adamas Pharmaceuticals), currently in Phase II/III. This is a product extension of amantadine and is not expected to have a significant impact on the market.
About This Report:
GlobalData, the industry analysis specialist, has released its new report, Dyskinesia Therapeutics - Pipeline Assessment and Market Forecasts to 2019. The report is an essential source of information and analysis on the global dyskinesia market.
The report identifies the key trends shaping and driving the global dyskinesia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global dyskinesia sector.
Scope:
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Dyskinesia Therapeutics market revenues data from 2006 to 2010, forecast for nine years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets.
- Analysis of the current and future competition in the seven key countries.
- Insightful review of the key industry drivers, restraints and challenges.
- Analysis of key recent licensing and partnership agreements.
Reasons to Buy:
- Develop and design your in-licensing and out-licensing strategies.
- Develop informed business strategies.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the market in future.
- Formulate effective sales and marketing strategies.
- Identify emerging players with potentially strong product portfolios.
For more information visit http://www.researchandmarkets.com/research/d6650b/dyskinesia_therape